Sonelokimab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Arthritis, Psoriatic
Conditions
Arthritis, Psoriatic
Trial Timeline
Nov 13, 2025 → Feb 4, 2028
NCT ID
NCT07223138About Sonelokimab
Sonelokimab is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Arthritis, Psoriatic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07223138. Target conditions include Arthritis, Psoriatic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07223138 | Phase 3 | Recruiting |
| NCT07007637 | Phase 3 | Recruiting |
| NCT06768671 | Phase 3 | Recruiting |
Competing Products
20 competing products in Arthritis, Psoriatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| Investigational Medical Product (IMP) administered in parent study | Eli Lilly | Phase 3 | 77 |
| Sonelokimab + Placebo + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Risankizumab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Sugar pill | Eli Lilly | Approved | 85 |
| Ixekizumab + Tirzepatide | Eli Lilly | Pre-clinical | 23 |
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| Ixekizumab + Adalimumab | Eli Lilly | Approved | 85 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |